Amirhossein Sahebkar

Amirhossein Sahebkar is an Iranian biotechnologist specializing in cardiovascular diseases. He is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences.

Life
Sahebkar completed a Pharm.D. in 2008 from Mashhad University of Medical Sciences. His dissertation was titled, An investigation of serum antibody titres to heat shock protein 27 (anti- Hsp27) as a biomarker for the detection of acute coronary syndrome. Sahebkar earned a Ph.D. in pharmaceutical biotechnology from the Mashhad University of Medical Sciences. His dissertation was titled, Preparation and evaluation of nanoliposomes conjugated with apolipoprotein B-100 antibodies as a therapeutic option for serum LDL reduction. He completed a postdoctoral fellowship in cardiometabolic diseases at the University of Western Australia.

Sahebkar is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences. His research focuses on cardiovascular disease, atherosclerosis, and blood lipids. He is a member of the Iran's National Elites Foundation. In 2016, he was presented the Professor Dr. Fereydoun Azizi award by the Iranian Academy of Medical Sciences.